Bacterial drug resistance overcome by synthetic restructuring of antibiotics

Nature ◽  
2021 ◽  
2017 ◽  
Vol 111 ◽  
pp. 468-471 ◽  
Author(s):  
Vivianne Marcelino de Medeiros ◽  
Yuri Mangueira do Nascimento ◽  
Augusto Lopes Souto ◽  
Sara Alves Lucena Madeiro ◽  
Vicente Carlos de Oliveira Costa ◽  
...  

2020 ◽  
Vol 2 (1) ◽  
pp. 5
Author(s):  
Sung-Won Kim

<p>The proportion of critically ill patients from neurosurgery wards in hospitals is significantly higher than that from other departments. These patients suffer from low immune. At the same time, because of the severe trauma after surgery and the complexity of pathogens in patients, antibiotics are frequently used. However, the of bacterial drug resistance is relatively high because of the particularity of hospitals, which is a major reason for the high infection rate of neurosurgery patients. Therefore, regarding to these risk factors, intervention measures should be actively explored in hospitals, so as to control the infection rate, reduce the possibility of infection in neurosurgery patients, improve the rehabilitation efficiency of patients, and reduce unnecessary suffering of patients caused by infection. This is also an effective means to improve the quality of hospital medical care. </p>


2018 ◽  
Vol 121 ◽  
pp. 293-302 ◽  
Author(s):  
Shafiul Haque ◽  
Faraz Ahmad ◽  
Sajad A. Dar ◽  
Arshad Jawed ◽  
Raju K. Mandal ◽  
...  

Author(s):  
John W. Wilson ◽  
Lynn L. Estes

This section contains tables covering spectrum of activity, preferred treatment and alternate treatment options various classes of bacteria, fungi, and viruses. Bacterial drug resistance issues are also reviewed.


2019 ◽  
Vol 22 ◽  
pp. S654
Author(s):  
B. Cabieses ◽  
A. Peters ◽  
M.P. Acuña ◽  
N. Uphoff ◽  
S. Astorga ◽  
...  

2017 ◽  
Vol 9 (22) ◽  
pp. 18512-18520 ◽  
Author(s):  
Jingxiao Tian ◽  
Jiangyan Zhang ◽  
Jiangtao Yang ◽  
Lingyun Du ◽  
Hao Geng ◽  
...  

2013 ◽  
Vol 57 (9) ◽  
pp. 4134-4138 ◽  
Author(s):  
Brian VanScoy ◽  
Rodrigo E. Mendes ◽  
Mariana Castanheira ◽  
Jennifer McCauley ◽  
Sujata M. Bhavnani ◽  
...  

ABSTRACTIn an era of rapidly emerging antimicrobial-resistant bacteria, it is critical to understand the importance of the relationships among drug exposure, duration of therapy, and selection of drug resistance. Herein we describe the results of studies designed to determine the ceftolozane-tazobactam exposure necessary to prevent the amplification of drug-resistant bacterial subpopulations in a hollow-fiber infection model. The challenge isolate was a CTX-M-15-producingEscherichia coliisolate genetically engineered to transcribe a moderate level ofblaCTX-M-15. This organism'sblaCTX-M-15transcription level was confirmed by relative quantitative reverse transcription-PCR (qRT-PCR), β-lactamase hydrolytic assays, and a ceftolozane MIC value of 16 mg/liter. In these studies, the experimental duration (10 days), ceftolozane-tazobactam dose ratio (2:1), and dosing interval (every 8 h) were selected to approximate those expected to be used clinically. The ceftolozane-tazobactam doses studied ranged from 125-62.5 to 1,500-750 mg. Negative- and positive-control arms included no treatment and piperacillin-tazobactam at 4.5 g every 6 h, respectively. An inverted-U-shaped function best described the relationship between bacterial drug resistance amplification and drug exposure. The least- and most-intensive ceftolozane-tazobactam dosing regimens, i.e., 125-62.5, 750-375, 1,000-500, and 1,500-750 mg, did not amplify drug resistance, while drug resistance amplification was observed with intermediate-intensity dosing regimens (250-125 and 500-250 mg). For the intermediate-intensity ceftolozane-tazobactam dosing regimens, the drug-resistant subpopulation became the dominant population by days 4 to 6. The more-intensive ceftolozane-tazobactam dosing regimens (750-375, 1,000-500, and 1,500-750 mg) not only prevented drug resistance amplification but also virtually sterilized the model system. These data support the selection of ceftolozane-tazobactam dosing regimens that minimize the potential for on-therapy drug resistance amplification.


Sign in / Sign up

Export Citation Format

Share Document